When acne debuts as acne fulminans — acne that manifests as an explosive worsening and ulceration of skin lesions and can be associated with systemic symptoms — heritability is a likely culprit. Dawn ...

Denifanstat met all endpoints in a Phase 3 acne trial and showed favorable tolerability. Sagimet also launched a Phase 1 trial for TVB-3567. Sagimet Biosciences announced that its oral fatty acid ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris. The company said that once daily oral 50 mg Denifanstat ...

A new study from researchers at Mass General Brigham examined how often, acne recurs after isotretinoin, the only approved medical treatment capable of inducing long-term remission of severe acne. The ...